PT  - JOURNAL ARTICLE
AU  - Hunter, Ruth F.
AU  - Garcia, Leandro
AU  - Stevenson, Mark
AU  - Nice, Kerry
AU  - Wijnands, Jasper S.
AU  - Kee, Frank
AU  - Ellis, Geraint
AU  - Anderson, Neil
AU  - Seneviratne, Sachith
AU  - Moeinaddini, Mehdi
AU  - Godic, Branislava
AU  - Akaraci, Selin
AU  - Thompson, Jason
TI  - Computer vision, causal inference and public health modelling approaches to generate evidence on the impacts of urban planning in non-communicable disease and health inequalities in UK and Australian cities: A proposed collaborative approach
AID  - 10.1101/2023.04.18.23288757
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.18.23288757
4099  - http://medrxiv.org/content/early/2023/04/19/2023.04.18.23288757.short
4100  - http://medrxiv.org/content/early/2023/04/19/2023.04.18.23288757.full
AB  - Background Given that the majority of the world’s population live in cities, it is essential to global health efforts that we design them in ways that both reduce non-communicable diseases (NCDs) risk and that facilitate adoption and maintenance of healthy lifestyles. Current approaches tend to focus on the relationship between urban design-related factors that affect health at the local or neighbourhood level but few studies have explored this relationship both within and across entire cities, nor explored the causal pathways between urban-designed related factors and NCDs. The aim of this research program is to use computer vision, causal inference, and public health modelling methods for understanding the causal relationship between urban design and health at the neighbourhood level, and to explore intervention approaches at the city scale.Methods Phase 1 will use machine learning and computer vision techniques to analyse gridded, local-level aerial images (with an optical resolution of <20cm), of all UK and Australian cities with populations over 100,000. It will identify a variety of urban features within these images and derive associations between them and NCD incidence and risk factors identified through location-based health surveys. Phase 2, using data from prospective health cohorts and linked objective built environment data, will apply Bayesian networks to investigate the possible causal pathways between built environment, lifestyle factors, and NCD incidence. Phase 3 will estimate the health impacts of actionable changes in urban design. Using health impact assessment modelling, we will calculate the NCD burden that could be prevented if cities were to adopt urban features of healthier counterparts. A similar approach will be applied on finer-grained scale within all case study cities, enabling assessment of health impacts of changes in individual locations. Phase 4 will develop an interactive web-based toolkit to enable urban designers, planners and policymakers to inform the decision-making cycle, co-designed with intended users involving participatory workshops.Discussion We use state-of-the-art approaches to: (i) generate evidence on the impacts of urban planning and design in NCDs and health inequalities in UK and Australian cities, and (ii) provide stakeholders with tools for advocacy and designing healthier cities.Trial registration Not applicable.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the MRC and NHMRC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study will use only openly available human data that were originally located at UK BiobankI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.ukbiobank.ac.uk/